Biogen
BIIB
BIIB
1,018 hedge funds and large institutions have $51.5B invested in Biogen in 2017 Q1 according to their latest regulatory filings, with 90 funds opening new positions, 389 increasing their positions, 395 reducing their positions, and 83 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
4% less capital invested
Capital invested by funds: $53.8B → $51.5B (-$2.28B)
25% less call options, than puts
Call options by funds: $808M | Put options by funds: $1.07B
34% less funds holding in top 10
Funds holding in top 10: 41 → 27 (-14)
Holders
1,018
Holding in Top 10
27
Calls
$808M
Puts
$1.07B
Top Buyers
| 1 | +$4.67B | |
| 2 | +$356M | |
| 3 | +$354M | |
| 4 |
Winslow Capital Management
Minneapolis,
Minnesota
|
+$345M |
| 5 |
Goldman Sachs
New York
|
+$121M |
Top Sellers
| 1 | -$727M | |
| 2 | -$466M | |
| 3 | -$336M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$164M |
| 5 |
Two Sigma Investments
New York
|
-$153M |